$190M US brain program is officially about stroke. Its real goal: immortality
MIT Technology Review's Antonio Regalado followed the money behind 'mind savers' and found a stroke-treatment program, a brain-freezing startup, and AI clones all chasing the same thing.
MIT Technology Review senior editor for biomedicine Antonio Regalado and science editor Mary Beth Griggs used the magazine's Roundtables event to unpack the 'mind savers' chasing cognitive immortality, including a $190 million US government brain-tissue program he calls a 'fig leaf' for living forever. For decision-makers, the signal is that longevity research is being funded and sold under medical labels long before the rules, pricing, or consent frameworks exist.
A $190 million US government program to develop replacement brain tissue is officially about treating stroke. According to Antonio Regalado, MIT Technology Review's senior editor for biomedicine, it is also 'a fig leaf for the actual ambition': living forever. Regalado spent months following the money, the science, and the philosophy behind the researchers he calls 'mind savers,' then sat down with science editor Mary Beth Griggs for the magazine's Roundtables event to explain what he found. His verdict, after all of it: part skeptical, part awestruck.
The number is the tell. A nine-figure public commitment framed around stroke rehabilitation is, in practice, seeding work that could one day let a brain outlast the body it came in. That is the pattern across the field. The projects that get funded, the startups that get pitched, and the ideas that get published rarely advertise themselves as immortality research. They arrive dressed as medicine. The mind savers are exploring everything from head transplants and brain freezing to conscious software avatars, and the packaging matters as much as the science, because the packaging is what unlocks the money.
The most plausible near-term version of the quest has nothing to do with surgery. Large language models are now good enough to build AI copies of people that act quite like the real thing. Regalado's framing of the ethical trap is blunt: 'This digital avatar might not be good enough for you, but what if it's good enough for me?' That one line splits the market in two. There is the high-fidelity version, where the copy has to satisfy the original's own standards, and the low-fidelity version, where the copy only has to satisfy the people who miss you. The second market is bigger, cheaper, and already technically within reach.
Then there is the hardware route. One company, Nectome, wants to preserve brains within 12 minutes of medically assisted death. Regalado's read on that pitch is not flattering: 'If you're selling a hot product, this is not it.' The business problem is structural rather than scientific. The customer has to die on schedule, in a place where medically assisted death is legal, with a preservation team standing by. That is a logistics nightmare wrapped around a grief product, and it helps explain why the sector has stayed small even as its ambition has stayed enormous.
Underneath all of it sits a question the engineers keep deferring. 'I'm not even sure that I have a very good claim to be myself,' Regalado said. If identity is already fuzzy, what exactly is being preserved? A wiring diagram? A conversational pattern? A set of memories that a model can imitate without ever having lived them? The mind savers are effectively betting that the answer is 'close enough,' and that the copy's behavior will matter more than its metaphysics. That is a testable bet in a lab and an untestable one in a family.
Regalado also found an unexpectedly practical upside to life as a brain in a jar: 'You can surf the internet. I do that pretty much 12 hours a day, anyway.' It is a joke, but it lands, because it reframes the entire enterprise. Strip away the transcendence and what is left is a pitch about continuity of experience, which is a product category consumers already understand and already pay for.
For executives and boards, the useful takeaway is not whether any of this works. It is that the funding mechanics are already live. A $190 million government program can be justified by stroke and then quietly widen the frontier of brain replacement. AI clones can be sold as memorial products long before anyone settles the consent questions. Brain preservation can be marketed to people who are already dying. In each case the technology is arriving ahead of the rules, the pricing, and the language we use to describe it. The people writing the checks are not waiting for a consensus on what a mind is, and neither are the people building the copies.
Regalado's posture, skeptical and awestruck at the same time, is probably the right one to copy. Not all of these projects are quite what they seem, and the ones that are real will not wait for permission. The full Roundtables conversation is available on demand to subscribers, and the through-line is worth carrying into your own planning: when someone sells you a stroke treatment, ask what else it is for.
This story's Key Insights and Take-aways are locked.
Create a free account to unlock Executive Actions for one credit.
Register to UnlockAlways free for Executives Club members. Join the Club
More in Technology
Anthropic mathematician claims Claude helped crack the Riemann hypothesis
If the proof holds, AI has toppled math's most famous open problem; if it does not, it is a case study in announcing breakthroughs before anyone verifies them.
AI's $4 Trillion Wipeout Erases Nasdaq's Gains for the Year
A brutal week took roughly $4 trillion off the AI sector and left the Nasdaq flat for the year, and the damage ran the full length of the supply chain.
Anthropic mathematician says AI proved the Riemann hypothesis. Verification will take time.
A single unverified claim from inside Anthropic now sits against more than 160 years of open mathematics, and the gap between asserting a proof and surviving peer review is the entire story.



